Intec Pharma Ltd. (NTEC) financial statements (2022 and earlier)

Company profile

Business Address 12 HARTOM STREET
JERUSALEM, 777512
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments10,135 17,07613,79910,89210,062
Cash and cash equivalents10,135 17,07613,79910,8929,292
Short-term investments     770
Restricted cash and investments1,000     
Receivables     3,683
Other undisclosed current assets1,024 6091,3072,638 
Total current assets:12,159 17,68515,10613,53013,745
Noncurrent Assets
Operating lease, right-of-use asset685 9549931,1171,243
Property, plant and equipment869 1,6801,9672,2722,575
Other noncurrent assets3,717 3,7173,7173,7173,717
Total noncurrent assets:5,271 6,3516,6777,1067,535
TOTAL ASSETS:17,430 24,03621,78320,63621,280
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:5,020 4,0193,9974,1874,835
Accounts payable336 5534042222
Accrued liabilities3,217 2,7042,7733,1162,838
Employee-related liabilities1,069 7356705251,431
Other undisclosed accounts payable and accrued liabilities398 27150524544
Other undisclosed current liabilities183 5313829303,507
Total current liabilities:5,203 4,5504,3795,1178,342
Noncurrent Liabilities
Long-term debt and lease obligation178 458536647799
Operating lease, liability178 458536647799
Liabilities, other than long-term debt705 951690652604
Other liabilities705 951690652604
Total noncurrent liabilities:883 1,4091,2261,2991,403
Total liabilities:6,086 5,9595,6056,4169,745
Stockholders' equity
Stockholders' equity attributable to parent11,344 18,07716,17814,22011,535
Common stock727 727727727727
Additional paid in capital218,397 217,330211,691206,786200,231
Accumulated deficit(207,780) (199,980)(196,240)(193,293)(189,423)
Total stockholders' equity:11,344 18,07716,17814,22011,535
TOTAL LIABILITIES AND EQUITY:17,430 24,03621,78320,63621,280

Income statement (P&L) ($ in thousands)

3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
Revenues     1,500
Gross profit:     1,500
Operating expenses(4,178) (3,641)(2,905)(3,739)(17,268)
Other undisclosed operating income    29,759
Operating loss:(4,178) (3,641)(2,905)(3,739)(6,009)
Loss from continuing operations before equity method investments, income taxes:(4,178) (3,641)(2,905)(3,739)(6,009)
Other undisclosed income (loss) from continuing operations before income taxes(31) (57)4(70)(9)
Loss from continuing operations before income taxes:(4,209) (3,698)(2,901)(3,809)(6,018)
Income tax expense(20) (42)(46)(61)(538)
Net loss available to common stockholders, diluted:(4,229) (3,740)(2,947)(3,870)(6,556)

Comprehensive Income ($ in thousands)

3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
Net loss:(4,229) (3,740)(2,947)(3,870)(6,556)
Comprehensive loss, net of tax, attributable to parent:(4,229) (3,740)(2,947)(3,870)(6,556)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: